The Evolving Role of Stroke Prediction Schemes for Patients With Atrial Fibrillation

Canadian Journal of Cardiology

Volumn 29, Issue 10, 2013, Pages 1173-1180

  Ha, Andrew ^a   Healey, Jeff S ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; TROPONIN I; WARFARIN;

ALCOHOL ABUSE; ANEMIA; ANTICOAGULANT THERAPY; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG USE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MORTALITY; PATIENT CARE; PREDICTION; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ATRIAL FIBRILLATION; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; HUMANS; INCIDENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; WORLD HEALTH;

EID: 84884591011     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.06.001     Document Type: Review

References (55)

1. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042-1046.
2. Furberg C.D., Psaty B.M., Manolio T.A. The prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). Am J Cardiol 1994, 74:236-241.
3. Kannell W.B., Abbot R.D., Savage D.D., et al. Epidemiologic features of chronic atrial fibrillation. The Framingham Study. NEngl J Med 1982, 306:1018-1022.
4. Krahn A.D. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Mainitoba Follow-up Study. Am J Med 1995, 98:476-484.
5. Hart R.G., Pearce L.A., Agullar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
6. Dentali F., Riva N., Crowther M., Turpie A.G., Lip G.Y., Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systemic review and meta-analysis of the literature. Circulation 2012, 126:2381-2391.
7. Gladstone D.J., Bui E., Fang J., et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009, 40:235-240.
8. Ogilvie I.M., Newton N., Welner S., et al. Underuse of oral anticoagulants in atrial fibrillation: a systemic review. Am J Med 2010, 123:638-645.
9. Bungard T.J., Ghali W.A., Teo K.K., et al. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 2000, 160:41-46.
10. Wolf P.A., Dawber T.R., Thomas H.E., et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978, 28:973-977.
11. Stroke risk in atrial fibrillation working group Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008, 39:1901-1910.
12. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
13. Wang T.J., Massaro J.M., Levy D., et al. Arisk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Study. JAMA 2003, 290:1049-1056.
14. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2879.
15. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010, 137:263-272.
16. Stroke Prevention in Atrial Fibrillation Investigators Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation study. JStroke Cerebrovasc Dis 1995, 5:147-157.
17. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287-2292.
18. Healey J.S., Hart R.G., Pogue J., et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W). Stroke 2008, 39:1482-1486.
19. Fang M.C., Go A.S., Chang Y., et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. JAm Coll Cardiol 2008, 51:810-815.
20. Olesen J.B., Lip G.Y., Hansen M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342:d124.
21. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
22. Banerjee A., Fauchier L., Vourc'h P., et al. Renal impairment and ischaemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. JAm Coll Cardiol 2013, 61:2079-2087.
23. Piccini J.P., Stevens S.R., Chang Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily Oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors in Atrial Fibrillation) study cohorts. Circulation 2013, 127:224-232.
24. Olesen J.B., Lip G.Y., Kamper A., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. NEngl J Med 2012, 367:625-635.
25. Lee M., Saver J.L., Chang K.H., Liao H.W., Chang S.C., Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 2010, 341:c4249.
26. Wizemann V., Tong L., Satayathum S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulation therapy. Kidney Int 2010, 77:1098-1106.
27. Chan K.E., Lazarus J.M., Thadhani R., Hakim R.M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. JAm Soc Nephrol 2009, 20:2223-2233.
28. Pisters R., Lane D.A., Nieuwlaat R., de Vos C., Crijns H.J., Lip G.Y. Anovel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
29. Gage B.F., Yan Y., Milligan P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.
30. Hijazi Z., Oldgren J., Adersson U., et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 2012, 125:1605-1616.
31. Roldan V., Marin F., Diaz J., et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. JThromb Haemost 2012, 10:1500-1507.
32. Bungard T.J., Ghali W.A., McAlister F.A., et al. Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ 2001, 165:301-302.
33. Man-Son-Hing M., Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003, 163:1580-1586.
34. Donze J., Rodondi N., Waeber G., Monney P., Cornuz J., Aujesky D. Scores to predict major bleeding during oral anticoagulation therapy: a prospective validation study. Am J Med 2012, 125:1095-1102.
35. Brimble K.S., Ingram A.J., Eikelboom J.W., Hart R.G. Anticoagulants in patients with atrial fibrillation and end-stage renal disease. Postgrad Med 2012, 124:17-25.
36. Shireman T.I., Mahnken J.D., Howard P.A., Kresowik T.F., Hou Q., Ellerbeck E.F. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006, 130:1390-1396.
37. Fang M.C., Go A.S., Chang Y., et al. Anew risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. JAm Coll Cardiol 2011, 58:395-401.
38. Olesen J.B., Lip G.Y., Hansen P.R., et al. Bleeding risk in "real world" patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. JThromb Haemost 2011, 9:1460-1467.
39. Cairns J.A., Connolly S.J., McMurtry S., et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
40. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm A.J., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) [erratum in 2011;32:1172]. Eur Heart J 2010, 31:2369-2429.
41. Connolly S.J., Eikelboom J.W., Ng J., et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011, 155:579-586.
42. Gage B.F., Birman-Deych E., Kerzner R., et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005, 118:612-617.
43. Man-Son-Hing M., Nichol G., Lau A., Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159:677-685.
44. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
45. Fang M.C., Go A.S., Chang Y., et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 2012, 43:1795-1799.
46. Gallego P., Roldan V., Torregrosa J.M., et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012, 5:312-318.
47. Steger C., Pratter A., Martinek-Bregel M., et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 2004, 25:1734-1740.
48. Lin H.J., Wolf P.A., Kelly-Hayes M., et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke 1996, 27:1760-1764.
49. Lamassa M., Di Carlo A., Pracucci G., et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001, 32:392-398.
50. McGrath E.R., Kapral M.K., Fang J., et al. Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation?. Stroke 2012, 43:2048-2054.
51. Lopes R.D., Al-Khatib S.M., Wallertin L., et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012, 380:1749-1758.
52. Friberg L., Rosenqvist M., Lip G.Y. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012, 125:2298-2307.
53. Vonkeman H.E., Fernades R.W., van der Palen J., van Roon E.N., van de Laar M.A. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal uclers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther 2007, 9:R52.
54. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin or both after myocardial infarction. NEngl J Med 2002, 347:969-974.
55. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. NEngl J Med 2011, 364:806-817.